Comment on: “Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors”

Ruyi Lei(First Affiliated Hospital of Zhengzhou University), Yu Jiang(Nanjing Tech University), Xiaoying Zhao(Handan College), Lin-Rong He(Southwest Medical University)
Hepatology International
July 2, 2025
10.1007/s12072-025-10861-z
Cited by 1

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247
Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis
|BMC Cancer|2014|146
Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis
|PLoS ONE|2015|115